Lupin Limited (LUPIN): research summary
Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Lupin Limited, explained in plain English.
- Lupin Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
- LUPIN closed at ₹2,014.00 on 20 November 2026.
- Over the past year the shares are down 0.8%, trading between ₹1,892.90 and ₹2,529.50.
- Reported fundamentals show return on equity of 23.85%, a net margin of 16.93%, debt to equity of 25.7.
- Our Pulse grade checklist scores it C (53/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
- Annualised volatility over the past year is 19.46% with a maximum drawdown of -23.57% and a beta of 0.48 against NIFTY 50.
Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma
Last traded values from 20 Nov 2026. Closed — weekend.
Pharma & Healthcare · Drug Manufacturers - Specialty & Generic
Lupin Limited (LUPIN)
₹1,998.8
▲ 26.9 (+1.36%)Price & volume
Hover for exact price & volume · green/red volume bars show up vs down days
Momentum check
Neutral momentum · 2/51M
+3.07%
3M
-10.17%
6M
-12.62%
1Y
-1.31%
Where it sits in its 52-week range
13%Below 52-week high
20.5%
4.0% above the low
Momentum read
Neutral
2/5 checks passed
52-wk high
₹2,514.8
52-wk low
₹1,922
Market cap
₹91,404 Cr
P/E (trailing)
17.6
Dividend yield
—
ROE
23.85%
Profit margin
16.93%
Revenue growth
11.1%
Price / Book
3.8
Debt / Equity
25.7
EPS (TTM)
113.48
Book value
₹526.08
Beta
0.48
Pulse grade: D, 46 out of 100
Momentum
F- ✕Trading above 50-day average
- ✕Trading above 200-day average
- ✓RSI in healthy 45-70 zone
- ✕Positive 3-month return
Growth
F- ✕Revenue growth above Pharma & Healthcare median (20.8%)
- ✓Revenue growing above 5%
- ✕Quarterly profits trending up
Profitability
A- ✓Return on equity above Pharma & Healthcare median (14.45%)
- ✓Return on equity above 12%
- ✓Profit margin above Pharma & Healthcare median (14.2%)
Safety
D- ✕Debt below Pharma & Healthcare median (17.71)
- ✓Debt not extreme for the sector
- ✓Less volatile than the market (beta < 1.2)
- ✕Pays a dividend
Quarterly revenue vs net profit
Sep 2026: revenue ₹7,786 crore · net profit ₹1,155 crore · margin 14.8%
Business quality
Intrinsic value
Analyst coverage
Who owns this company
Events, dividends & splits
Market position
Pharma & Healthcare sector
| Peer | Price ₹ | Day change | From 52-wk high |
|---|---|---|---|
| SUNPHARMA | 1,900 | +1.52% | -5.05% |
| DRREDDY | 1,400.9 | +0.19% | 0.00% |
| CIPLA | 1,418.5 | +0.11% | -7.37% |
| DIVISLAB | 11,178 | +1.17% | -3.35% |
| APOLLOHOSP | 8,738 | -0.94% | -3.65% |
| AUROPHARMA | 1,805.7 | +0.52% | -2.67% |
LUPIN headlines
No LUPIN stories right now.
LUPIN filings & announcements
LUPIN, historical timeline
The timeline will be ready shortly
The rest of the page is unaffected.
Risk & return, last 12 months
Volatility (ann.)
19.44%
Sharpe ratio
-0.31
Sortino ratio
-0.43
Max drawdown
-23.57%
Daily VaR (95%)
-1.7%
CAGR (1Y)
-1.58%
Return skew
-0.13
Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.
Risk profile over time
Performance at a glance
Quant tearsheet
Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.